Article Details

COMPARATIvE ANTI-INfLAMMATORy STUDIES ON TIMOLOL MALEATE AND DICLOfENAC SODIUM IN, IN VITRO AND IN VIVO MODELS by ORAL ROUTES

Namrata P. Nailwal a and Gaurav M. Doshia *

a Department of pharmacology, SVKm’s Dr. bhanuben Nanavati College of pharmacy, Vile Parle (W), Mumbai- 400 056, Maharashtra, India

* For Correspondence: e-mail: gaurav.pharmacology@gmail.com

 

https://doi.org/10.53879/id.60.09.13913


ABSTRACT

The present study was conducted on timolol maleate (a non-selective beta-blocker) using in vitro assays and in vivo models of rats. It was tested for its anti-inflammatory activity at three dose levels (1.028 mg kg-1 , 5.14 mg kg -1 and 10.28 mg kg -1). Furthermore, the investigation was supported by the estimation of tumor necrosis factor-alpha (tNF-α), interleukin-1 (IL- 1) and histopathological examination. It was observed that at 1.028 mg kg -1, 5.14 mg kg -1 and 10.28 mg kg -1 the drug showed anti-inflammatory activities. moreover, plasma levels of tNF-α and IL-1 showed inhibition. Histopathological examination confirmed the highest anti-inflammatory activity at 5.14 mg kg -1. Thus, the conducted studies revealed that timolol maleate, when given orally does possesses an anti-inflammatory potential.

Year 2023 | Volume No. 60 | Issue No.9 | Page No. 100-107
Recent Issue
Current Issue
June 2025
Quick Contact